At the news
? BEARISHIMPACT 7/10 S-3 filed Aug 28, 2026 at 17:04 ET
Spero Therapeutics filed a universal shelf registration statement (S-3) to register up to $300M in securities, including an immediate $100M at-the-market (ATM) common stock offering via Jefferies. The filing comes 16 days after a 10-Q showing a $70M market cap and a clinical-stage biotech with no approved products, making the ATM size (1.4x market cap) massively dilutive. This is a desperation capital raise to fund development of SP001, a preclinical CD40L antibody licensed from Innovent, with no near-term revenue prospects.
- S-3 registers up to $300M in securities (debt, common, preferred, warrants, units).
- Includes an immediate $100M ATM common stock offering via Jefferies (3% commission).
- ATM size ($100M) is ~143% of current $70M market cap, extreme potential dilution.
- Stock at $1.21/share; 58.1M shares outstanding as of June 30, 2026; ATM could add up to 82.6M shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access